-

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Stem, Inc. (STEM) and Encourages Long-Term STEM Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Stem, Inc. (NYSE: STEM) on behalf of the company’s long-term investors.

Stem is a provider of energy storage systems. The current company was formed in April 2021 via a business combination with SPAC entity Star Peak Energy Transition Corp. (NYSE: STPK), with Stem as the surviving, publicly traded entity.

Recently a securities fraud complaint was filed against Stem on behalf of certain investors who purchased shares of the company’s stock between December 4, 2020 and April 3, 2023 (inclusive). The complaint alleges that, during that time period, Stem and certain of the company’s executive officers made a series of false and misleading statements to investors about Stem’s business prospects, revenue streams, and financial results.

Immediately following the closing of the business combination in April 2021, shares of Stem’s stock traded as high as $36.38 per share. As further detailed in the complaint, however, Stem soon began reporting financial results that were dramatically worse than the company’s previously issued guidance. Following these disclosures, shares of Stem’s stock declined $28.08 per share, or over 75% in value, to close at $8.30 per share on February 16, 2023.

The investigation seeks to determine whether the members of Stem’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Current Stem stockholders who purchased or acquired their shares prior to December 4, 2020 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (skaskela@kaskelalaw.com / abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/stem/ , for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law LLC

NYSE:STEM

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law Firm Reports Ongoing Shareholder Investigation of Reservoir Media, Inc. and Encourages Investors to Contact the Firm – RSVR

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Reservoir Media, Inc. (NASDAQ: RSVR) on behalf of the company's shareholders....

Kaskela Law Firm Reports Ongoing Shareholder Investigation of Priority Technology Holdings, Inc. and Encourages Investors to Contact the Firm – PRTH

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC is conducting a stockholder investigation into Priority Technology Holdings, Inc. (NASDAQ: PRTH) (“Priority Technology”). The investigation seeks to determine whether Priority Technology and/or the company’s representatives violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Priority Technology shareholders should contact Kaskela Law (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 2...

SELECT MEDICAL STOCK ALERT: Does $16.50 Per Share Represent a Fair Shareholder Buyout Price? Kaskela Law Firm Announces Investigation into Fairness of Buyout Offer and Encourages Investors to Contact the Firm – SEM

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC is investigating the recently announced buyout of Select Medical Holdings Corp. (“Select Medical”) (NYSE: SEM) shareholders to determine whether the $16.50 per share buyout offer is fair to the company’s investors or if it undervalues the company’s shares. Click here for additional information: https://kaskelalaw.com/case/select-medical/ On March 2, 2026, Select Medical announced that it had agreed to be acquired by an investment consortium at a pr...
Back to Newsroom